Fatigue associated with chronic liver disease: A riddle wrapped in a mystery inside an enigma
E. Anthony Jones – 1 November 1995
Choline deficiency: A cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation
Alan L. Buchman, Mark D. Dubin, Adib A. Moukarzel, Donald J. Jenden, Margareth Roch, Kathleen M. Rice, Jeff Gornbein, Marvin E. Ament – 1 November 1995 – Patients receiving long‐term total parenteral nutrition (TPN) develop hepatic steatosis as a complication. Our previous studies have shown this to be caused, at least in part, by choline deficiency. We studied four patients (1 man, 3 women) aged 50 ± 13 years who had low plasma‐free choline concentrations 4.8 ± 1.7 (normal, 11.4 ± 3.7 nmol/mL). The patients had received TPN for 9.7 ± 4.7 years.
Notices
1 November 1995
FK506 in liver transplantation for chronic hepatitis B: In vitro studies on lymphocyte activation and virus replication
Philip Y. N. Wong, George Marinos, Mark Peakman, J. Michael Tredger, Johnson Y. N. Lau, Diego Vergani, Nikolai V. Naoumov, Professor Roger Williams – 1 November 1995 – Recurrence of hepatitis B virus (HBV) in the graft is the major problem for patients with chronic HBV infection undergoing liver transplantation, which could be potentiated by the immunosuppression.
Detection of hepatitis C virus with RNA polymerase chain reaction in fulminant hepatic failure
Federico G. Villamil, Ke‐Qin Hu, Chang‐Hong Yu, Chao‐Hung Lee, Sergio E. Rojter, Luis G. Podesta, Leonard Makowka, Stephen A. Geller, John M. Vierling – 1 November 1995 – The role of hepatitis C virus (HCV) infection in fulminant hepatic failure is controversial. The frequency of serum HCV RNA positivity in previously reported patients with fulminant hepatic failure (FHF) of indeterminate cause ranged from 0 to 12% in the United States and Europe and from 43% to 59% in Asia.
Nitric oxide donor prevents hepatic and systemic perfusion decrease induced by endotoxin in anesthetized rabbits
Catherine M. Pastor, Marie‐Reine Losser, Didier Payen – 1 November 1995 – Controversial studies have been published concerning the role of nitric oxide (NO) release (beneficial or deleterious) during sepsis. Severe hypotension has been treated by NO inhibitors in humans, but animal studies described an increased mortality rate with this treatment. We hypothesized that an NO donor might be beneficial in maintaining liver flow during endotoxemia.
The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: A conference sponsored by the national digestive diseases advisory board
Mitchell L. Shiffman, Lennox Jeffers, Jay H. Hoofnagle, Tommie Sue Tralka – 1 November 1995
Percutaneous venovenous bypass in orthotopic liver transplantation
W. Kenneth Washburn, W. David Lewis, Roger L. Jenkins – 1 November 1995 – Since January 1994, we have used percutaneous placement of both the subclavian and femoral cannulae to establish access for venovenous bypass during orthotopic liver transplantation. Percutaneous subclavian and femoral cannulae were used in 36 patients of which 5 had portal decompression by placement of a cannula in inferior mesenteric vein percutaneously through the abdominal wall.
Transjugular intrahepatic portosystemic shunt: Is it the ultimate solution for refractory ascites?
Florence Wong, Laurence Blendis – 1 November 1995 – Background. Previous studies have suggested that the transjugular placement of an intrahepatic stent to establish a portosystemic shunt is an effective treatment of uncomplicated ascites accompanying variceal bleeding. We studied the stent shunt for use in patients with liver cirrhosis and ascites refractory to medical treatment.